This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

NeurogesX, FDA Agree On Qutenza Study

SAN MATEO, Calif. (AP) ¿ NeurogesX Inc. said Wednesday it will study Qutenza as a treatment for nerve pain caused by shingles or diabetes, following an agreement with the Food and Drug Administration.

The drug will be tested as a potential treatment for post-herpetic neuralgia following pretreatment with an FDA-approved topical anesthetic.

The FDA is currently reviewing Qutenza as a potential treatment for the nerve pain condition, with a decision expected by Aug. 16.

The new study will involve 20 patients receiving the pain patch after a 60-minute pretreatment with an FDA-approved topical anesthetic. The goal of the study is the mean duration of the patch application.

Qutenza is already approved in Europe.

The drug had a slight setback in 2008, when it failed to reduce nerve pain in a late-stage study of HIV patients. At the time, though, it produced positive results in post-herpetic neuralgia.

Lazard Capital Markets analyst William Tanner reaffirmed a "Buy" rating and $8 target price on the stock, citing the study agreement with the FDA.

"Following European Union approval of Qutenza, we believe commercial prospects for the company are improving," he said, in a note to investors.

The company could announce a European partnership soon, he said.

Shares rose 14 cents, or 2.4 percent, to $6.09 in midday trading. The stock reached a new 52-week high of $6.25 earlier in the trading session.
Copyright 2009 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
NGSX $0.00 -28.57%
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs